An observational study in Heart Failure, sponsored by Abiomed Inc.. Terminated at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Abiomed Inc. (part of Johnson & Johnson) · Observational
Following an interim review, the sponsor determined that the current study design would not adequately address the study objectives. The study was therefore terminated early, and findings will inform future research.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Heart Failure by Johnson & Johnson — 2 open to participants now, 5 under way, none of them phase 3. Heart Failure · Johnson & Johnson.
Among the 43 studies in Heart Failure by Johnson & Johnson, this one is the only one that started in 2025, is one of 9 observational ones, and was the 40th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →2 of the 43 studies in Heart Failure by Johnson & Johnson are open now, in 1 country. Recruiting first, the newest first:
Abiomed Inc. · Sites in United States
Ages 18–80
V-Wave Ltd
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 12 · Phase 4 1
First in 1996; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 91 across the 33 interventional studies, 369 across the 9 observational. Of the 32 that completed or were terminated, 11 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Abiomed Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Abiomed Inc. is the lead sponsor of 34 studies on the registry; 5 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 43 studies in Heart Failure by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Analysis of cell and protein deposits on the Impella Heart Pump.
The Impella heart pump supports patients in cardiogenic shock for various reasons and has passed safety and biocompatibility evaluations. The planned investigation aims to further analyze cell and protein adhesion on these pumps and the effects of their prolonged use, especially in scenarios like bridge-to-transplant, recognizing preclinical testing limitations.
Patients treated with Impella CP or Impella 5.5 heart pump due to severe acute heart failure by any cause (e.g. cardiogenic shock in acute myocardial infarction, cardiac arrest, myocarditis or in relation to cardiac surgery).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients treated with Impella CP heart pump for more than 4 days due to severe acute heart failure by any cause
Patients treated with Impella 5.5 heart pump for more than or equal to 25 days due to severe acute heart failure by any cause
Investigate deposits and biomaterial after use of pump
investigate Impella CP after use regarding deposits and biomaterial
Time frame: through study completion, at least 5 days
Investigate deposits and biomaterial after use of pump
investigate Impella 5.5 pumps after use regarding deposits and biomaterial
Time frame: through study completion, at least 25 days
Relation deposits and biomaterial to clinical events
By correlating patient data, such as medical history and Impella CP related blood parameters, with the findings from our pump analysis, potential connections between medication, diseases, comorbidities, and deposits on the pump can be identified.
Time frame: through study completion, at least 5 days
Relation deposits and biomaterial to clinical events
By correlating patient data, such as medical history and Impella 5.5 related blood parameters, with the findings from our pump analysis, potential connections between medication, diseases, comorbidities, and deposits on the pump can be identified.
Time frame: through study completion, at least 25 days
Plan to share: Undecided — No publication planned yet
No publications or documents are linked to this record.
Ran from Sep 2025 to primary completion in Jun 2026, 9 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jul 2030 → Jun 2026 and completion Jan 2031 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Following an interim review, the sponsor determined that the current study design would not adequately address the study objectives. The study was therefore terminated early, and findings will inform future research.
Following an interim review, the sponsor determined that the current study design would not adequately address the study objectives. The study was therefore terminated early, and findings will inform future research.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.